Aureus Asset Management LLC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 8.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,161 shares of the company’s stock after acquiring an additional 1,876 shares during the quarter. Aureus Asset Management LLC’s holdings in Johnson & Johnson were worth $3,329,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in JNJ. Pachira Investments Inc. grew its stake in shares of Johnson & Johnson by 12.2% in the first quarter. Pachira Investments Inc. now owns 4,424 shares of the company’s stock worth $551,000 after acquiring an additional 480 shares during the period. Schaper Benz & Wise Investment Counsel Inc. WI grew its position in Johnson & Johnson by 0.5% during the first quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 114,681 shares of the company’s stock valued at $14,283,000 after buying an additional 544 shares during the period. Cedar Wealth Management LLC grew its position in Johnson & Johnson by 5.3% during the first quarter. Cedar Wealth Management LLC now owns 3,294 shares of the company’s stock valued at $410,000 after buying an additional 167 shares during the period. Usca Ria LLC grew its position in Johnson & Johnson by 4.7% during the first quarter. Usca Ria LLC now owns 49,607 shares of the company’s stock valued at $6,179,000 after buying an additional 2,244 shares during the period. Finally, Willingdon Wealth Management grew its position in Johnson & Johnson by 11.8% during the first quarter. Willingdon Wealth Management now owns 12,958 shares of the company’s stock valued at $1,614,000 after buying an additional 1,372 shares during the period. Hedge funds and other institutional investors own 65.90% of the company’s stock.

Shares of Johnson & Johnson (JNJ) traded up $0.58 during trading hours on Friday, reaching $140.59. 5,100,000 shares of the company’s stock traded hands, compared to its average volume of 4,754,087. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a twelve month low of $110.76 and a twelve month high of $144.35. The stock has a market capitalization of $377,697.84, a P/E ratio of 19.69, a P/E/G ratio of 2.86 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same quarter in the previous year, the firm earned $1.68 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. research analysts expect that Johnson & Johnson will post 7.28 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.39%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is currently 58.33%.

Several analysts recently issued reports on the stock. Piper Jaffray Companies restated a “hold” rating and set a $120.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 4th. Vetr lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price for the company. in a research report on Monday, September 18th. Stifel Nicolaus boosted their target price on shares of Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research report on Wednesday, October 18th. UBS restated a “buy” rating and set a $148.00 target price on shares of Johnson & Johnson in a research report on Thursday, August 31st. Finally, Wells Fargo & Company upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $140.00 to $149.00 in a research report on Monday, October 9th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $144.59.

COPYRIGHT VIOLATION NOTICE: “Johnson & Johnson (JNJ) Shares Bought by Aureus Asset Management LLC” was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/johnson-johnson-jnj-shares-bought-by-aureus-asset-management-llc/1756101.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.